ArticleJHLT open2025
Heart transplantation in special patient populations.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review of heart transplantation (HTx) in special patient populations, the indications for HTx for patients with underlying genetic conditions, myopathies, mitochondrial conditions, connective tissue disorders (CTDs), and intellectual developmental delay will be explored along with the outcomes and survival. A key principle for cardiologists looking after these patients who may develop end-stage heart failure and require HTx evaluation is to determine what is in the child's best interest from a medical, physical, emotional, developmental, and psychosocial perspective with a goal of providing the child not only survival but an acceptable quality of life within their underlying circumstances. This review highlights that much like clinicians do for any pediatric patient put forward for HTx and as the International Society of Heart Lung Transplantation (ISHLT) endorses an evaluation of the patient's cardiopulmonary status, comorbidities and psychosocial factors that may affect graft/patient survival should be considered for patients with underlying genetic conditions, myopathies, CTDs, and intellectual delays prior to transplantation. More research is required to better understand the risk and long-term outcomes of HTx in those with underlying mitochondrial conditions where HTx has accelerated the progression of disease in other organ systems and in conditions such as Noonan's syndrome, where patients have a higher risk of developing post-transplant complications such as post-transplant lymphoproliferative disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.